Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;45(11):2193-2200.
doi: 10.1007/s40618-022-01872-w. Epub 2022 Jul 22.

Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study

R Modica #  1 , C Scandurra #  2 , N M Maldonato  2 , P Dolce  3 , G G Dipietrangelo  4 , R Centello  5 , V Di Vito  5 , E Giannetta  4 , A M Isidori  4 , A Lenzi  4 , A Faggiano  5 , A Colao  6   7
Affiliations

Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study

R Modica et al. J Endocrinol Invest. 2022 Nov.

Abstract

Purpose: Scientific knowledge on health-related quality of life (HRQoL) in patients with neuroendocrine neoplasm (NEN) is still limited and longitudinal assessment of HRQoL over the time in NEN patients are scarce. The current study aimed to assess the role of clinical severity and heterogeneity of NEN, as well as resilience, in the HRQoL of NEN patients over the course of a year.

Methods: 39 consecutive NEN patients (25 men and 14 women) aged from 29 to 73 years participated in a longitudinal Italian multicentric study. The main outcome measure concerned the severity and heterogeneity of NEN, HRQoL, and resilience.

Results: Over the course of a year, higher levels of the global health (GH) were associated to the absence of distant metastases, while the presence of metastases with higher levels of fatigue, diarrhea, and financial difficulties. Higher levels of resilience are still associated with better GH and lower levels of fatigue, diarrhea, and financial difficulties, but no longer with constipation. Furthermore, patients with gastroenteropancreatic NEN still have higher scores on constipation, but not on GH, fatigue, diarrhea, and financial difficulties. Patients with hereditary NEN continue to have greater GH than those with a sporadic NEN and lower fatigue, diarrhea, and financial difficulties.

Conclusion: These findings showed that the effects of severity and clinical heterogeneity of the NEN on HRQoL may change over time. This evidence should lead clinicians to monitor the HRQoL of NEN patients throughout the course of the disease and psychologists to implement evidence-based resilience interventions.

Keywords: HRQoL; Metastases; Neuroendocrine tumor; Quality of life; Resilience; Severity.

PubMed Disclaimer

Conflict of interest statement

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

    1. Frilling A, Åkerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19:163–185. doi: 10.1530/ERC-12-0024. - DOI - PubMed
    1. Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, di Vito V, Bottiglieri F, de Cicco F, Giannetta E, Isidori AM, Lenzi A, Muzii B, Faggiano A, Colao A. Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metab. 2021;106:e316–e327. doi: 10.1210/clinem/dgaa760. - DOI - PubMed
    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43. doi: 10.1007/s11912-021-01029-7. - DOI - PMC - PubMed
    1. Faggiano A, lo Calzo F, Pizza G, Modica R, Colao A, The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017;16:1149–1161. doi: 10.1080/14740338.2017.1354984. - DOI - PubMed